Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ENT011
MIFTS: 55

Enterocolitis

Categories: Gastrointestinal diseases, Infectious diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Enterocolitis

About this section

MalaCards integrated aliases for Enterocolitis:

Name: Enterocolitis 57 28 53 16 71 75

Characteristics:


Inheritance:

Autosomal recessive 57

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

OMIM® 57 226150
ICD10 31 A04.7
MedGen 40 C0014356
UMLS 71 C0014356
Sources

Summaries for Enterocolitis

About this section

MalaCards based summary: Enterocolitis is related to food allergy and patent ductus arteriosus 1. An important gene associated with Enterocolitis is NLRC4 (NLR Family CARD Domain Containing 4), and among its related pathways/superpathways are Innate Immune System and Prolactin Signaling. The drugs Zinc cation and Zinc sulfate have been mentioned in the context of this disorder. Affiliated tissues include small intestine, bone marrow and colon, and related phenotypes are hematochezia and abdominal distention

Wikipedia: 75 Enterocolitis is an inflammation of the digestive tract, involving enteritis of the small intestine and... more...

More information from OMIM: 226150
Sources

Related Diseases for Enterocolitis

About this section

Diseases related to Enterocolitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1206)
# Related Disease Score Top Affiliating Genes
1 food allergy 31.2 TNF IL10 CXCL8
2 patent ductus arteriosus 1 30.9 IL6 CXCL8 CRP
3 perinatal necrotizing enterocolitis 30.6 TNF TLR4 TFF3 NOD2 IL6 IL10
4 campylobacteriosis 30.6 TLR4 IL10
5 diarrhea 30.5 TNF TLR4 NOD2 IL6 IL10 CXCL8
6 ileus 30.5 TNF IL6 IL10 CRP
7 asphyxia neonatorum 30.4 IL6 CRP
8 human cytomegalovirus infection 30.4 TNF IL6 IL10
9 intestinal obstruction 30.3 TNF NOD2 IL6 CRP
10 paralytic ileus 30.3 IL6 CRP
11 intestinal perforation 30.2 TNF NOD2 IL6 IL10 FABP2 CRP
12 neutropenia 30.2 TNF TLR4 IL6 IL10 CXCL8 CRP
13 gastroenteritis 30.2 TNF IL6 IL10 CXCL8 CRP
14 toxic megacolon 30.2 TNF CRP
15 volvulus of midgut 30.2 FABP2 CRP
16 inflammatory bowel disease 1 30.2 TNF TLR4 NOD2 IL6 IL10
17 compartment syndrome 30.2 TNF IL6 CRP
18 mucositis 30.2 TLR4 IL10 HMGB1
19 periventricular leukomalacia 30.1 TNF IL6 CXCL8 CRP
20 esophagitis 30.0 TNF IL6 IL10 CXCL8
21 fasciitis 30.0 TNF IL6 CXCL8
22 cholera 30.0 TNF IL6 IL10 CXCL8
23 mucormycosis 30.0 TNF IL6 IL10 CRP
24 allergic disease 30.0 TNF IL6 IL10 CXCL8
25 acquired immunodeficiency syndrome 30.0 TNF IL6 IL10 CRP
26 granulomatous hepatitis 30.0 TNF CRP
27 typhoid fever 30.0 TNF TLR4 IL6 CRP
28 exudative vitreoretinopathy 1 30.0 TNF IL6 IL10 CXCL8 CRP
29 gas gangrene 30.0 TNF IL6 CRP
30 ileocolitis 29.9 TNF NOD2
31 acute diarrhea 29.9 IL10 CXCL8 CRP
32 gastritis 29.9 TNF TLR4 IL6 IL10 CXCL8
33 henoch-schoenlein purpura 29.9 TNF IL6 CRP
34 ischemic colitis 29.9 TNF IL6 FABP2 CRP
35 plague 29.9 TNF TLR4 IL6 IL10
36 polyarteritis nodosa 29.9 TNF IL6 CRP
37 common cold 29.8 TNF IL6 IL10 CXCL8 CRP
38 dysentery 29.8 TNF TLR4 IL6 IL10 CXCL8 CRP
39 intestinal tuberculosis 29.8 TNF NOD2 CRP
40 crohn's disease 29.8 TNF TLR4 NOD2 IL6 IL10 CXCL8
41 candidiasis 29.8 TNF TLR4 IL6 IL10 CXCL8
42 myocarditis 29.8 TNF TLR4 IL6 IL10 CXCL8
43 disseminated intravascular coagulation 29.8 TNF IL6 IL10 HMGB1 CRP
44 viral infectious disease 29.8 TNF TLR4 IL6 IL10 CXCL8
45 exanthem 29.8 TNF IL6 IL10 CXCL8 CRP
46 vasculitis 29.8 TNF IL6 IL10 CXCL8 CRP
47 bowel dysfunction 29.7 TNF NOD2 IL6 IL10 FABP2 CRP
48 inflammatory diarrhea 29.7 IL10 CXCL8
49 uremia 29.7 TNF IL6 CRP
50 thrombocytopenia 29.7 TNF TLR4 IL6 IL10 CXCL8 CRP

Graphical network of the top 20 diseases related to Enterocolitis:



Diseases related to Enterocolitis
Sources

Symptoms & Phenotypes for Enterocolitis

About this section

Human phenotypes related to Enterocolitis:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hematochezia 30 HP:0002573
2 abdominal distention 30 HP:0003270
3 enterocolitis 30 HP:0004387
4 ulcerative colitis 30 HP:0100279

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
G I:
ulcerative colitis
bloody diarrhea
pseudomembranous enterocolitis

Abdomen:
swelling

Clinical features from OMIM®:

226150 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Enterocolitis according to GeneCards Suite gene sharing:

25 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.72 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.72 IL10
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.72 CRP
4 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.72 IL10
5 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.72 TLR4
6 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.72 CRP
7 Increased shRNA abundance (Z-score > 2) GR00366-A-148 9.72 CRP
8 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.72 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.72 CRP IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.72 IL10
11 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.72 IL10 NOD2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.72 IL10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.72 TLR4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.72 NOD2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.72 IL10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-53 9.72 IL10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.72 CRP
18 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.72 IL10
19 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.72 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-68 9.72 IL10 TLR4
21 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.72 IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.72 IL10

MGI Mouse Phenotypes related to Enterocolitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 CD14 CRP FABP2 HBEGF HMGB1 IL10
2 immune system MP:0005387 9.9 CD14 CRP FABP2 HMGB1 IL10 IL6
3 respiratory system MP:0005388 9.5 CD14 HBEGF HMGB1 IL10 IL6 TLR4
4 skeleton MP:0005390 9.23 CD14 HBEGF IL10 IL6 NLRC4 NOD2
Sources

Drugs & Therapeutics for Enterocolitis

About this section

Drugs for Enterocolitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
2
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
5
Iron Approved Phase 4 7439-89-6 29936
6
Ceftriaxone Approved Phase 4 73384-59-5 5479530
7
Adalimumab Approved, Experimental Phase 4 331731-18-1
8
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
9
Azithromycin Approved Phase 4 83905-01-5 447043
10
Fidaxomicin Approved Phase 4 873857-62-6 151383
11
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
12
Beta carotene Approved, Nutraceutical Phase 4 6811-73-0, 7235-40-7 10256668 5280489
13
Picolinic acid Investigational Phase 4 98-98-6 1018
14 Trace Elements Phase 4
15 Micronutrients Phase 4
16 Hormones Phase 4
17 Dermatologic Agents Phase 4
18 Antineoplastic Agents, Hormonal Phase 4
19 Carotenoids Phase 4
20 Iron Chelating Agents Phase 4
21 Calciferol Phase 4
22 Hormone Antagonists Phase 4
23 Provitamins Phase 4
24 Antiemetics Phase 4
25 glucocorticoids Phase 4
26 Antiprotozoal Agents Phase 4
27 Antiparasitic Agents Phase 4
28 Anti-Inflammatory Agents Phase 4
29 Amebicides Phase 4
30 Antirheumatic Agents Phase 4
31 Gentamicins Phase 4
32 Antibiotics, Antitubercular Phase 4
33
Rifampicin Approved Phase 3 13292-46-1 135512673 5381226 135900090
34
Nitazoxanide Approved, Investigational, Vet_approved Phase 3 55981-09-4 41684
35
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
36
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
37
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
38
Clarithromycin Approved Phase 3 81103-11-9 84029
39
Cysteine Approved, Nutraceutical Phase 2, Phase 3 52-90-4 594 5862
40
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 68-26-8 5280382 445354
41 Amino-acid, glucose, and electrolyte solution Phase 2, Phase 3
42 Parenteral Nutrition Solutions Phase 2, Phase 3
43 Antitubercular Agents Phase 3
44 Bifidobacterium Phase 3
45 Retinol palmitate Phase 3
46 Anesthetics Phase 3
47
Pentoxifylline Approved, Investigational Phase 2 6493-05-6 4740
48
Cefoxitin Approved Phase 2 35607-66-0 441199
49
Cefotaxime Approved Phase 2 63527-52-6 5742673 456256
50
Indomethacin Approved, Investigational Phase 2 53-86-1 3715

Interventional clinical trials:

(show top 50) (show all 215)
# Name Status NCT ID Phase Drugs
1 The Effect of Withholding Feeds During Red Blood Cell Transfusion on Development of TRAGI in Very Low Birth Weight Infants Unknown status NCT02132819 Phase 4
2 Oral Zinc Supplementation Improving Growth and Reducing Morbidity on Very Low Birth Weight Infant Unknown status NCT04050488 Phase 4 Zinc Sulfate;Placebos
3 The Effect of Co-administered β-Carotene, Vitamin D3, Zinc and Antenatal Steroid Therapy on Hyaline Membrane Disease and Feeding Intolerance in Premature Neonates Unknown status NCT03366584 Phase 4 Dexamethasone
4 Probiotics for Prophylaxis of Postoperative Hirschsprungs Associated Enterocolitis Unknown status NCT02343562 Phase 4
5 The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis Unknown status NCT01278017 Phase 4 ceftriaxone
6 Effect of Melatonin on Feeding Intolerance and Incidence of Necrotizing Enterocolitis in Preterm Infants Completed NCT04304807 Phase 4 Melatonin 20 mg;Traditional antibiotic treatment
7 Postmarketing Study of Probiotics Medication in Childhood Diarrhea Completed NCT00463190 Phase 4 Biothree
8 Exploratory Study of Impact of Oral Metronidazole, Vancomycin and Fidaxomicin on the Extent and Quantity of Host Carriage and Environmental Contamination With C. Difficile Completed NCT02057198 Phase 4 Fidaxomicin;Metronidazole;Vancomycin
9 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
10 NICU Antibiotics and Outcomes Trial Recruiting NCT03997266 Phase 4 Ampicillin;Gentamycin;Normal saline
11 The Efect of Azithromicyn on Bronchopulmonary Displasia in Extremely Preterm and Very Preterm Infant Recruiting NCT05311228 Phase 4 Azithromycin Powder
12 New Treatment Strategy for Patients With Multiple Recurrent Clostridioides Difficile Infection With Bezlotoxumab as First Option Not yet recruiting NCT05077085 Phase 4 Bezlotoxumab;Vancomycin oral
13 The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study Terminated NCT00164099 Phase 4 Synbiotic 2000
14 Addition of a Probiotic (Lactobacillus GG) to Metronidazole for the Treatment of Clostridium Difficile Associated Disease Withdrawn NCT00304863 Phase 4 Lactobacillus GG
15 Effect of Cysteine Supplementation on Glutathione Production in Critically Ill Neonates Unknown status NCT00254176 Phase 2, Phase 3
16 Role Of Saccharomyces Boulardii in Preventin Necrotizing Enterocolitis in Very Low Birth Weight Infants Unknown status NCT01315821 Phase 3 Saccharomyces boulardii;Placebo
17 Can Bovine Lactoferrin Prevent Neonatal Infections in Low Birth Weight Babies in Karachi, Sindh, Pakistan. Unknown status NCT03431558 Phase 3 Glucon-D 99.4% (Placebo)
18 Prospective, Randomized Study of Oral Metronidazole vs. Oral Metronidazole and Rifampin for Treatment of Clostridium Difficile-associated Diarrhea (CDAD) Completed NCT00182429 Phase 3 Metronidazole and Rifampin
19 The Efficacy of Symbiotic Preparation on Cytokines Which Act on Necrotising Enterocolitis Pathogenesis in Very Low Birth Weight Infants Completed NCT01899677 Phase 3 symbiotic
20 Role of Probiotics for Prevention of Necrotizing Enterocolitis in Preterm Very Low Birth Weight Infants: A Double Blind Randomized Controlled Trial Completed NCT02650869 Phase 3
21 The Use of Probiotics in the Management of Necrotizing Enterocolitis in HIV-exposed Premature and Very-low Birth Weight Infants Completed NCT01868737 Phase 3
22 Effect of Vitamin A in the Treatment of Sepsis and Necrotizing Enterocolitis in Hospitalized Neonates Completed NCT00707785 Phase 3
23 Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy Completed NCT00304356 Phase 3 Nitazoxanide
24 A Randomized, Double-Blind Study of GT267-004 Versus Vancomycin, and GT267-004 Versus Metronidazole, in Patients With C.Difficile - Associated Diarrhea Completed NCT00106509 Phase 3 tolevamer potassium-sodium (GT267-004)
25 A Randomized, Double-Blind Study of GT267-004 Versus Vancomycin, and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea Completed NCT00196794 Phase 3 Tolevamer potassium-sodium (GT267-004)
26 Nosocomial Infections and Necrotizing Enterocolitis in Preterm Neonates Treated With Lactobacillus Acidophilus and Bifidobacterium Infantis in An Intensive Care Unit : A Randomized Controlled Study Completed NCT01340469 Phase 3
27 Role Of Lactobacillus Reuteri in Preventing Necrotizing Enterocolitis in Very Low Birth Weight Infants Completed NCT01531179 Phase 3 Lactobacillus reuteri;Placebo
28 A Prospective, Multi-center, Randomized Trial of Fecal Microbiota Transplantation (FMT) Delivered by Capsule vs Colonoscopy in the Management of Recurrent Clostridium Difficile Infection (CDI) Completed NCT02254811 Phase 2, Phase 3
29 Nordic Study on Human Milk Fortification in Extremely Preterm Infants: a Randomized Controlled Trial Recruiting NCT03797157 Phase 2, Phase 3
30 Evaluation of Bowel Perfusion With Contrast-Enhanced Ultrasound in Necrotizing Enterocolitis Recruiting NCT03549507 Phase 3 Sulfur hexafluoride lipid-type A microspheres
31 A Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IBP-9414 in Premature Infants 500-1500g Birth Weight in the Prevention of Necrotizing Enterocolitis - The Connection Study Recruiting NCT03978000 Phase 3 IBP-9414;Placebo
32 Treatment of Classic Mid-trimester Preterm Premature Rupture of Membranes (PPROM) With Oligo/Anhydramnion Between 22/0-26/0 Week of Gestation by Means of Continuous Amnioinfusion: a Multicenter Prospectiv Randomized Trial Not yet recruiting NCT04696003 Phase 3
33 An Open-label Study to Assess the Safety, Efficacy and Absorption of Exodifâ„¢ (Tolevamer Potassium Sodium) Tablets in Patients With Clostridium Difficile-Associated Diarrhea Terminated NCT00466635 Phase 3 GT267-004 (tolevamer potassium sodium)
34 Heat Killed Probiotics in the Prevention of Necrotizing Enterocolitis (NEC) in Premature Neonates Unknown status NCT02796703 Phase 2
35 Effectiveness and Safety of Intravenous Infusion of Bone Marrow Derived Allogeneic Multipotent Mesenchymal Stromal Cells for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis in Hematological Patients With Aplasia After High-dose Chemotherapy. Unknown status NCT02145923 Phase 1, Phase 2 High-dose chemotherapy;Bone marrow derived allogeneic MMSCs infusion
36 Prebiotics vs. Placebo in the Prevention of Necrotizing Enterocolitis in Premature Neonates Unknown status NCT00437567 Phase 2
37 Pentoxifylline in the Treatment of Necrotizing Enterocolitis in Premature Neonates Unknown status NCT00271336 Phase 2 Pentoxifylline
38 The Role of Lactobacillus Reuteri (L. Reuteri) in Preventing Necrotizing Enterocolitis (NEC) in Pre-term Infants Less Than 34 Weeks of Gestation Unknown status NCT04541771 Phase 2 Lactobacillus Reuteri DSM 17938;Placebo
39 Antibiotic Effects on the Developing Microbiome, Metabolome and Morbidities in Preterm Neonates Completed NCT02784821 Phase 2 Antibiotic;Antibiotics - pre-emptive
40 Erythropoietin Protects Very Preterm Infants Against Necrotizing Enterocolitis Completed NCT03919500 Phase 2 EPO;Normal saline
41 Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus in Preterm infants-a Multicenter Trial Completed NCT01958320 Phase 2 NSAID
42 A Randomized, Double Blind, Parallel-group, Dose Escalation Placebo-controlled Multicenter Study to Investigate the Safety and Tolerability of IBP-9414 Administered in Preterm Infants. Completed NCT02472769 Phase 2 IBP-9414;Placebo
43 A Randomized, Double-Blind Study of GT160-246 Versus Vancomycin in Patients With C. Difficile-Associated Diarrhea Completed NCT00034294 Phase 2 GT160-246
44 Prophylactic Probiotics to Extremely Low Birth Weight Prematures Completed NCT01603368 Phase 2
45 Multiple Dose Pharmacokinetic Study of Meropenem in Young Infants (<91 Days) With Suspected or Complicated Intra-abdominal Infections Completed NCT00621192 Phase 1, Phase 2 meropenem
46 The Effects of Lactulose Supplementation to Enteral Feedings in Premature Infants - A Pilot Study Completed NCT00616876 Phase 2 Lactulose
47 Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies Completed NCT01674478 Phase 2
48 Enteral Granulocyte Colony Stimulating Factor and Erythropoietin Early in Life Increases Feeding Tolerance in Preterm Infants: A Randomized Controlled Trial Completed NCT01441427 Phase 1, Phase 2 recombinant human G-CSF, and rhEPO;rh G-CSF;rh EPO;rh G-GSF and rh EPO together;Placebo
49 Efficacy of Enteral Administration of the Docosahexaenoic Acid on Necrotizing Enterocolitis, Cytokines and Hospital Stay in Preterm Neonates Completed NCT01745510 Phase 1, Phase 2
50 Incidence of Severe Necrotizing Enterocolitis in Preterm Newborns <1500g Using Probiotics Lactobacillus Boucardii. Completed NCT02226263 Phase 2

Search NIH Clinical Center for Enterocolitis

Sources

Genetic Tests for Enterocolitis

About this section

Genetic tests related to Enterocolitis:

# Genetic test Affiliating Genes
1 Enterocolitis 28
Sources

Anatomical Context for Enterocolitis

About this section

Organs/tissues related to Enterocolitis:

MalaCards : Small Intestine, Bone Marrow, Colon, Breast, Neutrophil, Myeloid, Bone
Sources

Publications for Enterocolitis

About this section

Articles related to Enterocolitis:

(show top 50) (show all 13595)
# Title Authors PMID Year
1
Early lethal autosomal recessive enterocolitis: report of a second family. 62 57
17204052 2007
2
A lethal autosomal recessive entero-colitis of early infancy. 57
4426135 1974
3
[Gastrointestinal abnormalities in children with autism]. 53 62
19650428 2009
4
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. 53 62
16710025 2006
5
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. 53 62
16224277 2005
6
A human yeast artificial chromosome containing the multiple endocrine neoplasia type 2B Ret mutation does not induce medullary thyroid carcinoma but does support the growth of kidneys and partially rescues enteric nervous system development in Ret-deficient mice. 53 62
15632018 2005
7
Inflammatory changes secondary to postoperative complications of Hirschsprung's disease as a cause of histopathologic changes typical of intestinal neuronal dysplasia. 53 62
14966730 2004
8
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. 53 62
12826605 2003
9
Piperacillin/tazobactam in comparison with clindamycin plus gentamicin in the treatment of intra-abdominal infections. 53 62
7553416 1995
10
Milk-induced eczema is associated with the expansion of T cells expressing cutaneous lymphocyte antigen. 53 62
7532192 1995
11
Food protein-induced enterocolitis to casein hydrolysate formulas. 53 62
8258625 1993
12
Posterior reversible encephalopathy syndrome and necrotizing enterocolitis in a pediatric patient with medulloblastoma and COVID-19 infection. 62
35841310 2023
13
Protease inhibitor from Libidibia ferrea seeds attenuates inflammatory and nociceptive responses in mice. 62
36096346 2023
14
Dual medication therapy (acetaminophen and ibuprofen) for the management of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. 62
36008521 2022
15
Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study. 62
36149461 2022
16
The role of gastrostomy feeding during intestinal rehabilitation for children with short bowel syndrome. 62
36462084 2022
17
Effects of prophylactic indomethacin on morbidity and mortality in infants <25 weeks' gestation: a protocol driven intention to treat analysis. 62
36310242 2022
18
Growth trajectory of preterm small-for-gestational-age neonates. 62
34503371 2022
19
Comparison the efficacy of vaginal progesterone versus 17-alpha-hydroxyprogesterone caproate to prevent preterm birth in high-risk pregnant women undergo cerclage: a randomized clinical trial. 62
34470137 2022
20
The Possible Protective Role of Bilirubin on Oxidative Stress Related Morbidity in Preterm Infants. 62
34821525 2022
21
Late preterm births: neonatal mortality and morbidity in twins vs. singletons. 62
34154507 2022
22
Impact of a Standardized Nutrition Bundle Including Donor Human Milk on Hospital Outcomes in Very Low Birth-Weight (VLBW) Infants in a Safety-Net Hospital. 62
36413779 2022
23
Metabolic differences among newborns born to mothers with a history of leukemia or lymphoma. 62
33980115 2022
24
Bacterial endotoxin-induced maternal inflammation leads to fetal intestinal injury and affects microbial colonization in the neonatal period. 62
34058958 2022
25
Birthweight and Apgar at 5 minutes of life for the prediction of severe neonatal outcomes in preterm prelabor rupture of membranes. 62
33403889 2022
26
Effect of hydrolyzed formulas on gastrointestinal tolerance in preterm infants: a systematic review and meta-analysis. 62
36104076 2022
27
The role of the first trimester screen in the face of normal cell free DNA. 62
35603424 2022
28
Cesarean delivery at term for non-reassuring fetal heart rate tracing: risk factors and predictability. 62
33969774 2022
29
Feeding during therapeutic hypothermia is safe and may improve outcomes in newborns with perinatal asphyxia. 62
35164630 2022
30
Neonatal outcome of second-stage cesarean delivery versus vacuum extraction among neonates <34 weeks. 62
33928834 2022
31
Prevalence of major morbidities and outcome of all hospitalized neonates. A retrospective cohort study of Huai'an neonatal survivals. 62
35341440 2022
32
Gastroschisis: a systematic review of diagnosis, prognosis and treatment. 62
33899664 2022
33
Changes in postoperative quality of life of pediatric total colonic aganglionosis patients: effect of pull-through technique. 62
36173457 2022
34
Effects of less invasive surfactant administration versus intubation-surfactant-extubation on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome: a single-center, retrospective study from China. 62
36471386 2022
35
A comparison of the effect of bi-level positive airway pressure and synchronized intermittent mandatory ventilation in preterm infants with respiratory distress syndrome. 62
33573450 2022
36
Prophylactic versus therapeutic caffeine for apnea of prematurity: a randomized controlled trial. 62
33771081 2022
37
Predicting clinical outcomes using artificial intelligence and machine learning in neonatal intensive care units: a systematic review. 62
35562414 2022
38
Association of inotrope use with neurodevelopmental outcomes in infants <29 weeks gestation: a retrospective cohort study. 62
33827395 2022
39
Clinical impact of severe acute kidney injury on post-operative and brain injury outcomes in preterm infants following surgical necrotizing enterocolitis. 62
36093832 2022
40
Transfusion-associated necrotizing enterocolitis (NEC) in extremely preterm infants: experience of a tertiary neonatal center in UK. 62
33472464 2022
41
Update on Immune Checkpoint Inhibitor Enterocolitis. 62
36264425 2022
42
Hypoxia-Inducible Factor 1α Stability Modified by Glutaredoxin-1 in Necrotizing Enterocolitis. 62
36049244 2022
43
Astaxanthin Reduces the Severity of Intestinal Damage in a Neonatal Rat Model of Necrotizing Enterocolitis. 62
33853144 2022
44
Reducing Risk Factors for Necrotizing Enterocolitis: What Is the Recent Evidence and Biologic Plausibility Supporting Probiotics? 62
35446273 2022
45
Capecitabine-induced enterocolitis: a case report and pharmacogenetic profile. 62
36382550 2022
46
Review of Necrotizing Enterocolitis and Spontaneous Intestinal Perforation Clinical Presentation, Treatment, and Outcomes. 62
36328610 2022
47
Age disparities in intestinal stem cell quantities: a possible explanation for preterm infant susceptibility to necrotizing enterocolitis. 62
36208323 2022
48
Heme induces intestinal epithelial cell ferroptosis via mitochondrial dysfunction in transfusion-associated necrotizing enterocolitis. 62
36383399 2022
49
Gestational age-specific hematological patterns in preterm infants following necrotizing enterocolitis. 62
36062737 2022
50
Sildenafil attenuates intestinal injury in necrotizing enterocolitis independently of endothelial nitric oxide synthase. 62
35794042 2022
Sources

Variations for Enterocolitis

About this section
Sources

Expression for Enterocolitis

About this section
Search GEO for disease gene expression data for Enterocolitis.
Sources

Pathways for Enterocolitis

About this section

Pathways related to Enterocolitis according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.85 CD14 CRP CXCL8 HMGB1 IL10 IL6
2
Prolactin Signaling 64
Show member pathways
 13.37 TNF TLR4 IL6 HMGB1 HBEGF CD14
3
Cytokine Signaling in Immune system 66
Show member pathways
 13.24 TNF NOD2 IL6 IL10 HMGB1 CXCL8
4
Toll-like receptor signaling pathway 74
Show member pathways
 12.78 TNF TLR4 IL6 CXCL8 CD14
5
Malignant pleural mesothelioma 74
12.61 IL6 IL10 HMGB1 HBEGF
6
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.57 CXCL8 HBEGF IL10 IL6 TNF
7
Immune response IL-23 signaling pathway 22
Show member pathways
 12.53 TNF IL6 IL10 CD14
8
DDX58/IFIH1-mediated induction of interferon-alpha/beta 66
Show member pathways
 12.41 TLR4 HMGB1 CXCL8 CD14
9
Bacterial infections in CF airways 22
Show member pathways
 12.35 CD14 CXCL8 IL6 TLR4 TNF
10
Toll Comparative Pathway 64
Show member pathways
 12.26 TNF TLR4 IL6 CXCL8 CD14
11
Sudden infant death syndrome (SIDS) susceptibility pathways 74
12.14 CXCL8 IL10 IL6 TNF
12
Neuroinflammation and glutamatergic signaling 74
12.02 TNF IL6 IL10
13
Toll-Like receptor Signaling Pathways 65
Show member pathways
 12 TNF TLR4 NOD2 NLRC4 IL6 CXCL8
14
Hematopoietic Stem Cells and Lineage-specific Markers 65
11.98 TNF IL6 IL10 CD14
15
Spinal cord injury 74
11.97 TNF TLR4 IL6 CXCL8
16
Interleukin-4 and Interleukin-13 signaling 66
11.93 TNF IL6 IL10 CXCL8
17
IL27-mediated signaling events 61
Show member pathways
 11.88 TNF TLR4 IL6 IL10
18
CCL18 signaling pathway 74
11.85 IL6 IL10 CXCL8
19
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 11.85 TLR4 IL6 CXCL8 CD14
20
Mesenchymal Stem Cells and Lineage-specific Markers 65
11.84 IL6 HBEGF CD14
21
Allograft rejection 74
11.83 TNF IL10 CXCL8
22
Network map of SARS-CoV-2 signaling pathway 74
Show member pathways
 11.74 IL6 CXCL8 CRP
23
Burn wound healing 74
11.73 TNF TLR4 IL6 HMGB1 CXCL8
24
Acute viral myocarditis 74
11.72 TLR4 IL6 IL10
25
Dendritic Cells Developmental Lineage Pathway 65
11.72 TNF IL6 IL10 CD14
26
AP-1 transcription factor network 61
11.68 IL6 IL10 CXCL8
27
Extrafollicular B cell activation by SARS-CoV-2 74
11.65 TNF TLR4 IL6 IL10 CRP
28
Photodynamic therapy-induced NF-kB survival signaling 74
Show member pathways
 11.64 TNF IL6 CXCL8
29
Lung fibrosis 74
11.63 TNF IL6 CXCL8
30
NF-kB (NFkB) Pathway 67
11.57 TNF TLR4 CD14
31
Transcription_NF-kB signaling pathway 22
11.56 TNF TLR4 CD14
32
IL 10 signaling pathway 67
11.56 CD14 IL10 IL6 TLR4 TNF
33
SARS-CoV-2 innate immunity evasion and cell-specific immune response 74
11.53 TNF IL10 CXCL8
34
Interleukin-10 signaling 66
11.51 TNF IL6 IL10 CXCL8
35
miRNAs involvement in the immune response in sepsis 74
11.51 CXCL8 IL10 IL6 TLR4 TNF
36
Fibrin complement receptor 3 signaling pathway 74
11.46 TNF TLR4 IL6 CD14
37
Inflammatory bowel disease signaling 74
Show member pathways
 11.43 TNF TLR4 NOD2 IL6 IL10
38
Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway 74
11.29 TNF IL6 CXCL8
39
Cytokines and inflammatory response 74
11.27 TNF IL6 IL10
40
amb2 Integrin signaling 61
11.26 TNF IL6 HMGB1
41
Non-genomic actions of 1,25 dihydroxyvitamin D3 74
11.26 TNF TLR4 NOD2 IL6 CXCL8
42
Prostaglandin signaling 74
11.24 TNF IL6 CXCL8
43
Immune infiltration in pancreatic cancer 74
11.23 TNF IL6 IL10 CXCL8
44
LDL- influence on CD14 and TLR4 74
11.1 CD14 IL10 IL6 TLR4
45
Overview of nanoparticle effects 74
11.01 TNF IL6 CXCL8 CRP
46
MIF Action Through Endocytic Pathway 64
10.78 TLR4 CD14
47
COVID-19 adverse outcome pathway 74
10.69 CXCL8 IL6
48
IL-10 Pathway 64
10.57 TNF TLR4 IL6 IL10 CD14
49
Cells and molecules involved in local acute inflammatory response 74
Show member pathways
 10.39 TNF IL6 CXCL8
Sources

GO Terms for Enterocolitis

About this section

Cellular components related to Enterocolitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.21 TNF TFF3 IL6 IL10 HMGB1 HBEGF
2 cell surface GO:0009986 9.7 CD14 HBEGF HMGB1 NOD2 TLR4 TNF
3 extracellular space GO:0005615 9.58 TNF TFF3 IL6 IL10 HMGB1 HBEGF
4 lipopolysaccharide receptor complex GO:0046696 9.46 TLR4 CD14

Biological processes related to Enterocolitis according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 10.4 TLR4 NOD2 NLRC4 HMGB1 CRP CD14
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.3 TNF TLR4 NOD2 HMGB1
3 defense response to bacterium GO:0042742 10.22 IL10 NLRC4 NOD2 TLR4 TNF
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.2 TNF TLR4 NOD2 NLRC4 IL6
5 positive regulation of MAP kinase activity GO:0043406 10.19 TNF TLR4 NOD2
6 positive regulation of type II interferon production GO:0032729 10.19 TNF TLR4 CD14
7 positive regulation of MAPK cascade GO:0043410 10.19 HMGB1 IL6 NOD2 TNF
8 phagocytosis GO:0006909 10.18 TLR4 NOD2 CD14
9 positive regulation of JNK cascade GO:0046330 10.18 TNF TLR4 NOD2 HMGB1
10 immune response GO:0006955 10.17 TNF TLR4 IL6 IL10 CXCL8
11 negative regulation of tumor necrosis factor production GO:0032720 10.16 TLR4 NOD2 IL10
12 negative regulation of interleukin-6 production GO:0032715 10.16 TNF TLR4 IL10
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.16 TNF TLR4 NOD2 CD14
14 response to glucocorticoid GO:0051384 10.15 TNF IL6 IL10
15 defense response to Gram-positive bacterium GO:0050830 10.15 TNF NOD2 IL6 CRP
16 JNK cascade GO:0007254 10.14 TNF TLR4 NOD2
17 positive regulation of smooth muscle cell proliferation GO:0048661 10.14 HBEGF IL6 TLR4 TNF
18 response to activity GO:0014823 10.12 TNF IL6 IL10
19 positive regulation of chemokine production GO:0032722 10.11 TNF TLR4 IL6
20 positive regulation of interleukin-12 production GO:0032735 10.11 HMGB1 NOD2 TLR4
21 positive regulation of tumor necrosis factor production GO:0032760 10.1 TLR4 NOD2 IL6 HMGB1 CD14
22 positive regulation of cytokine production GO:0001819 10.09 CD14 IL10 TNF
23 lipopolysaccharide-mediated signaling pathway GO:0031663 10.09 CD14 TLR4 TNF
24 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.09 TNF IL6 IL10
25 immune system process GO:0002376 10.08 TLR4 NOD2 NLRC4 HMGB1 CD14
26 I-kappaB kinase/NF-kappaB signaling GO:0007249 10.07 TNF TLR4 NOD2
27 liver regeneration GO:0097421 10.07 IL10 IL6 TNF
28 positive regulation of interleukin-6 production GO:0032755 10.07 TNF TLR4 NOD2 IL6 HMGB1
29 negative regulation of type II interferon production GO:0032689 10.06 TLR4 NOD2 IL10 HMGB1
30 inflammatory response GO:0006954 10.06 CD14 CRP CXCL8 HMGB1 IL6 NLRC4
31 positive regulation of interleukin-10 production GO:0032733 10.03 HMGB1 IL6 NOD2 TLR4
32 cellular response to lipoteichoic acid GO:0071223 10 CD14 TLR4
33 positive regulation of neuroinflammatory response GO:0150078 10 IL6 TNF
34 activation of innate immune response GO:0002218 10 TLR4 NLRC4 HMGB1
35 response to lipopolysaccharide GO:0032496 10 TNF TLR4 NOD2 IL10 CD14
36 nucleotide-binding oligomerization domain containing 2 signaling pathway GO:0070431 9.99 TLR4 NOD2
37 vascular endothelial growth factor production GO:0010573 9.97 IL6 TNF
38 negative regulation of lipid storage GO:0010888 9.97 TNF IL6 CRP
39 positive regulation of oxidative stress-induced neuron death GO:1903223 9.96 TNF TLR4
40 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.96 TNF NOD2
41 positive regulation of interleukin-1 beta production GO:0032731 9.96 TNF TLR4 NOD2 NLRC4 IL6
42 negative regulation of cytokine production involved in immune response GO:0002719 9.95 TNF IL10
43 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.95 TNF TLR4 HMGB1
44 negative regulation of interleukin-18 production GO:0032701 9.93 NOD2 IL10
45 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.92 IL6 NOD2 TLR4 TNF
46 response to molecule of bacterial origin GO:0002237 9.91 IL10 CXCL8 CD14
47 chronic inflammatory response to antigenic stimulus GO:0002439 9.88 TNF IL10
48 response to peptidoglycan GO:0032494 9.86 IL6 NOD2
49 cellular response to molecule of bacterial origin GO:0071219 9.84 CD14 TNF
50 positive regulation of interleukin-8 production GO:0032757 9.73 TNF TLR4 NOD2 IL6 HMGB1 CD14

Molecular functions related to Enterocolitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopolysaccharide binding GO:0001530 9.43 TLR4 HMGB1 CD14
2 cytokine activity GO:0005125 9.28 TNF IL6 IL10 HMGB1 CXCL8
Sources

Sources for Enterocolitis

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....